Acasă › Cancer colorectal › Tennessee
Studii clinice pentru Cancer colorectal în Tennessee
76 studii pentru Cancer colorectal caută participanți în Tennessee.
Orașe în Tennessee
Text oficial al studiului (în engleză)
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Vanderbilt University/Ingram Cancer Center, Nashville
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT05673148The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
În curs de recrutareFaza 1/2
Vârste de 12 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT04585750A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT06270706A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT06760819Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #3, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT05176483Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT06625775Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT05877599A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- Sarah Cannon Research Institute Oncology Partners, Nashville
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT07659795Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT05803382Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07222800A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Vanderbilt Ingram Cancer Center, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05379595A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07277270Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06218914Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Vanderbilt University Medical Center, Nashville
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT04981119A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06004245A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Tennessee Oncology Chattanooga, Chattanooga
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
- și încă 1
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06750094A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06662786Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Vanderbilt University/Ingram Cancer Center, Nashville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT05863195Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT06047379A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Local Institution - 0333, Nashville
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 23 sept. 2026 · NCT07221357Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
În curs de recrutareFaza 2
Vârste de la 18 la 130 · Toate sexele · Actualizat 23 sept. 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06445062A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Tennessee Oncology, PLLC, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07629960Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT05786924A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT07213609A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Provision Center For Biomedical Research, Knoxville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 15 sept. 2026 · NCT07284849A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT04929223A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- SCRI Oncology Partners, Nashville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT07549412A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT06440005Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- Vanderbilt University/Ingram Cancer Center, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT06696768Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Germantown
- Clinical Study Site, Hermitage
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT07228832Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Tennessee Oncology PLLC - Chattanooga, Nashville
- Tennessee Oncology, PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT06252649A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Vanderbilt University Medical Center, Nashville
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 sept. 2026 · NCT06992258A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 27 aug. 2026 · NCT07544589Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT04851119MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Sarah Cannon Research Institute, Nashville
- USO - US Oncology Research Network, Nashville
- Vanderbilt University School of Medicine, Nashville
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 aug. 2026 · NCT06586515A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- Research Site, Nashville
În curs de recrutareFaza 2
Vârste de la 18 la 130 · Toate sexele · Actualizat 18 aug. 2026 · NCT06792695FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT05919264Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.